Calif. ephedra bill
This article was originally published in The Tan Sheet
Executive Summary
SB 1884 (formerly SB 1750) passes state Assembly Aug. 31, has been sent to Gov. Gray Davis (D). Sponsored by Sen. Jackie Speier (D-Burlingame), bill would prohibit sale of ephedrine alkaloid supplements to minors, place more stringent warnings, FDA MedWatch number, on labeling. Davis, who vetoed similar bill in 2000, has until the end of September to sign SB 1884. In an Aug. 15 letter to FDA, Calif. Department of Health Services Director Diana Bonta, PhD, said "absent significant immediate action by the federal government to protect the public health, I intend to recommend that the governor sign this legislation" (1"The Tan Sheet" Aug. 26, 2002, p. 11)...
You may also be interested in...
Metabolife Proposes NIH “Blue Ribbon” Commission To Complement RAND
Only 50 to 150 of Metabolife 356's 13,000 HealthLine patient calls appear to involve significant events such as stroke or acute cardiac symptoms, according to analyses by three reviewers retained by Metabolife
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.